Results 71 to 80 of about 71,439 (210)

Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with Sorafenib with or without Erlotinib in the SEARCH Trial [PDF]

, 2016
Purpose: Sorafenib is the current standard therapy for advanced HCC, but validated biomarkers predicting clinical outcomes are lacking. This study aimed to identify biomarkers predicting prognosis and/or response to sorafenib, with or without erlotinib,
Evans, T.R. Jeffrey, Gane, Edward, Jeffers, Michael, Kang, Yoon-Koo, Meinhardt, Gerold, Peña, Carol E.A., Rosmorduc, Olivier, Ross, Paul, Santoro, Armando, Vogel, Arndt, Zhu, Andrew X.   +10 more
core   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 333-350, June 2026.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. [PDF]

, 2019
PurposeDiarrhea is recognized as a common adverse event associated with tyrosine kinase inhibitors (TKIs), with those targeting the ErbB family of receptors being associated with the highest rate of diarrhea.MethodsThis paper reviews data on the ...
Bosserman, Linda, Bryce, Richard, Di Palma, Jack A, Moran, Susan, Olek, Elizabeth, Rugo, Hope S, Tripathy, Debu   +6 more
core  

Real‐World Survival Outcomes in EGFR‐Mutant Advanced NSCLC Treated With EGFR TKIs: Insights From a Single‐Center Clinical Data Warehouse Analysis in South Korea

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 464-472, June 2026.
This retrospective cohort study was conducted using clinical data derived from a single‐center clinical data warehouse (CDW). In Korean patients with EGFR‐mutant advanced NSCLC, first‐line treatment with 3G EGFR TKIs (osimertinib or lazertinib) demonstrated significantly better overall survival than 1G or 2G agents.
Bomi Kim, Sunghoon Kang, Iksoo Huh, Hyeoneui Kim   +3 more
wiley   +1 more source

Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.

PLoS ONE, 2013
Epidermal growth factor receptor (EGFR) is extensively expressed in head and neck cancer. However, EGFR-targeted therapy has only modest efficacy in head and neck cancer, through mechanisms that are not fully understood. Here, we found that inhibition of
Rui Li, Shuo You, Zhongliang Hu, Zhuo G Chen, Gabriel L Sica, Fadlo R Khuri, Walter J Curran, Dong M Shin, Xingming Deng   +8 more
doaj   +1 more source

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells [PDF]

, 2015
Epidermal growth factor receptor (EGFR), member of the human epidermal growth factor receptor (HER) family, plays a critical role in regulating multiple cellular processes including proliferation, differentiation, cell migration and cell survival ...
Cardinali, Beatrice, FUSTAINO, VALENTINA, GIANNINI, Giuseppe, LALLI, CRISTIANA, Papoff, Giuliana, PRESUTTI, DARIO, Ruberti, Giovina, Samperna, Simone, Santini, Simonetta   +8 more
core   +3 more sources

Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF‐PARAGON study)

International Journal of Cancer, Volume 158, Issue 10, Page 2560-2570, 15 May 2026.
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Thorsten O. Goetze, Salah‐Eddin Al‐Batran, Ruediger Liersch, Lars Scheuer, Thomas Goehler, Ulrich Kaiser, Claudio Denzlinger, Stephan Brandl, Daniel Pink, Jens Uhlig, Michael Maasberg, Maria Loose, Marina Schaaf, Disorn Sookthai, Bianca Zäpf, Claudia Pauligk, Timursah Habibzade, Ralf‐Dieter Hofheinz, Christine Koch, for the AIO Study Group   +19 more
wiley   +1 more source

Second line therapy in malignant pleural mesothelioma: a systematic review [PDF]

, 2015
After the implementation of standard first line chemotherapy with platinum and antifolates in pleural mesothelioma, patients are confronted with a need for second line treatment at relapse or progression.
Baas, Paul, Buikhuisen, Wieneke A, Hiddingab, Birgitta I, Van Meerbeeck, Jan   +3 more
core   +2 more sources

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, Volume 32, Issue 17, 5 May 2026.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression

Biomolecules, 2020
An adverse reaction of dry skin occurs frequently during treatment with anticancer epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
Nobutomo Ikarashi, Miho Kaneko, Tomofumi Watanabe, Risako Kon, Makana Yoshino, Takatoshi Yokoyama, Riho Tanaka, Naoya Takayama, Hiroyasu Sakai, Junzo Kamei   +9 more
doaj   +1 more source